Pharmacotherapy of kidney stones

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 9, 2008, Pages 1509-1518

  Pak, Charles Y C ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Hypercalciuria; Hyperxaluria; Potassium citrate; Renal stone

Indexed keywords

ALLOPURINOL; CALCITRIOL; CALCIUM; CALCIUM OXALATE; CHLORTALIDONE; CITRATE CALCIUM; CITRATE POTASSIUM; CITRATE SODIUM; CITRIC ACID; CYSTINE; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; INDAPAMIDE; MAGNESIUM; OXALIC ACID; PARATHYROID HORMONE; PLACEBO; POTASSIUM CHLORIDE; POTASSIUM SALT; SODIUM; SODIUM CHLORIDE COTRANSPORTER; THIAZIDE DIURETIC AGENT; TIOPRONIN; TOPIRAMATE; TRIAMTERENE; UNINDEXED DRUG; URATE; UREA; VITAMIN D RECEPTOR; XANTHINE OXIDASE; URIC ACID;

ACIDURIA; BONE DENSITY; CALCIUM STONE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CYSTINE STONE; DIARRHEA; DIET RESTRICTION; DIET THERAPY; DIFFERENTIAL DIAGNOSIS; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DYSLIPIDEMIA; ENVIRONMENTAL FACTOR; ENZYME INHIBITION; HEMATOLOGIC DISEASE; HOMOCYSTINURIA; HUMAN; HYPERCALCIURIA; HYPERCITRATURIA; HYPERGLYCEMIA; HYPEROXALURIA; HYPERURICEMIA; HYPERURICOSURIA; HYPOCHLOREMIA; HYPOCITRATURIA; HYPOKALEMIA; KIDNEY DISEASE; LIVER DYSFUNCTION; LIVER FUNCTION; LOOSE FECES; METABOLIC ALKALOSIS; METABOLIC DISORDER; MUSCLE CRAMP; NAUSEA; NEPHROLITHIASIS; NONHUMAN; PATHOPHYSIOLOGY; PHYSICAL CHEMISTRY; PROTEIN INTAKE; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SKIN DEFECT; SKIN MANIFESTATION; SODIUM INTAKE; SODIUM URINE LEVEL; URIC ACID STONE; URINE PH; URINE VOLUME; VOMITING; ANIMAL; METABOLISM; RECURRENT DISEASE; URINE;

ANIMALS; CITRIC ACID; HUMANS; HYPERCALCIURIA; HYPEROXALURIA; KIDNEY CALCULI; RECURRENCE; URIC ACID;

EID: 46749139508     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.9.1509     Document Type: Review

References (47)

1. Hosking DH, Erickson EB, van den Berg CJ, et al. The stone clinic effect in patients with idiopathic calcium urolithiasis. J Urol 1983;130:1115-8
2. Pak CYC, Skurla C, Harvey JA. Graphic display of urinary risk factors for renal stone formation. J Urol 1985;134:867-70
3. Mandel NS, Mandel GS. Physicochemistry of urinary stone formation. In: Pak CYC, editor, Renal Stone disease: pathogenesis, prevention and treatment. Matinus Nijhoff Publishing: Boston, MA; 1987. p. 1-24
4. Pak CYC, Poindexter J, Adams-Huet B, Pearle MS. Predictive value of kidney stone composition in the detection of metabolic abnormalities. Am J Med 2003;115:26-32
5. Daudon M, Lacour B, Jungers P. High prevalence of uric acid calculi in diabetic stone formers. Nephrol Dial Transplant 2005;20:468-9
6. Henneman PH, Benedict PH, Forbes AP, Dudley HR. Idiopathic hypercalciuria. N Engl J Med 1958;259:802-7
7. Yao J, Kathpalia P, Bushinsky DA, Favus MJ. Hyperresponsiveness of vitamin D receptor gene expression to 1,25-dihydroxyvitamin D3. J Clin Invest 1998;101:2223-32
8. Reed BY, Gitomer WL, Heller H, et al. Identification and characterization of a gene with base substitutions associated with the absorptive hypercalciuria phenotype and low spinal bone density. J Clin Endocrinol Metab 2002;87:1476-85
9. Heller HJ, Zerwekh JE, Gottschalk FA, Pak CYC. Increased bone resorption and reduced bone formation in moderate-severe absorptive hypercalciuria: bone histomorphometric analysis and alendronate challenge. Kidney Int 2007;71:808-15
10. Odvina CV, Sakhaee K, Heller H, et al. Biochemical characterization of primary hyperparathyroidism with and without kidney stones. Urol Res 2007;35:123-8
11. Moe OW, Preisig PA. Dual role of citrate in mammalian urine. Curr Opin Nephrol Hypertens 2005;15:419-24
12. Coe FL, Moran E, Kavalich AG. The contribution of dietary purine over-consumption to hyperuricosuria in calcium oxalate stone formers. J Chron Dis 1976;29:793-800
13. Coe F, Raisen L. Allopurinol treatment of uric acid disorders in calcium-stone formers. Lancet 1973;i:129-31
14. Grover PK, Ryall RL, Marshall VR. Dissolved urate promotes calcium oxalate crystallization; epitaxy is not the cause. Clin Sci 1993;85:303-7
15. Ettinger B, Tang A, Citron JT, et al. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med 1986;315:1386-9
16. Sakhaee K, Adams-Huet B, Moe OW, Pak CYC. Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney Int 2002;62:971-9
17. Abate N, Chandalia M, Cabo-Chan AV, et al. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int 2004;65:386-92
18. Sakhaee K, Harvey JA, Padalino PK, et al. Potential role of salt abuse on the risk for kidney stone formation. J Urol 1991;150:310-2
19. Reddy ST, Wang CY, Sakhaee K, Pak CYC. Effect of low carbohydrate, high protein diets on acid-base balance, stone-forming propensity and calcium metabolism. Am J Kidney Dis 2002;40:265-74
20. Borghi L, Meschi T, Amato F, et al. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol 1996;155:839-43
21. Coe FL. Treated and untreated recurrent calcium nephrolithiasis in patients with idiopathic hypercalciuria, hyperuricosuria or no metabolic disorder. Ann Int Med 1977;87:404-10
22. Borghi L, Meschi T, Guerra A, Novarini A. Randomized prospective study of a non-thiazide diuretic, indapamide, in preventing calcium stone recurrences. J Cardiovasc Pharmacol 1993;22:578-86
23. Nicar MJ, Peterson R, Pak CYC. Use of potassium citrate as potassium supplement during thiazide therapy of calcium nephrolithiasis. J Urol 1984;131:430-3
24. Huen SC, Goldfarb DS. Adverse metabolic side effects of thiazides: implications for patients with calcium nephrolithiasis. J Urol 2007;177:1238-43
25. Leppla D, Browne R, Hill K, Pak CYC. Effect of amiloride with at without hydrochlorothiazide on urinary calcium and saturation of calcium salts. J Clin Endocrinol Metab 1983;57:920-4
26. Yeh BI, Sun TJ, Lee JZ, et al. Mechanism and molecular determinant for regulation of rabbit transient receptor potential type 5 (TRPV5) channel by extracellular pH. J Biol Chem 2003;278:51044-52
27. Sakhaee K, Alpern R, Jacobson HR, Pak CYC. Contrasting effects of various potassium salts on renal citrate excretion. J Clin Endocrinol Metab 1991;72:396-400
28. Sakhaee K, Nicar MJ, Hill K, Pak CYC. Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming salts. Kidney Int 1983;24:348-52
29. Odvina CV, Preminger GM, Lindberg JS, et al. Long-term combined treatment with thiazide and potassium citrate in nephrolithiasis does not lead to hypokalemia or hypochloremic metabolic alkalosis. Kidney Int 2003;63:240-7
30. Hatch M, Cornelius J, Allison M, et al. Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion. Kidney Int 2006;69:691-8
31. Hoppe B, Beck B, Garter N, et al. Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1. Kidney Int 2006;70:1305-11
32. Pak CYC, Peterson R. Successful treatment of hyperuricosuric calcium oxalate nephrolithiasis with potassium citrate. Arch Intern Med 1986;146:863-8
33. Parks JH, Worcester EM, Coe FL, et al. Clinical implications of abundant calcium phosphate in routinely analyzed kidney stones. Kidney Int 2004;66:777-85
34. Goldfarb DS, Coe FL, Asplin J. Urinary cystine excretion and capacity in patients with cystinuria. Kidney Int 2006;69:1041-7
35. Pak CYC, Fuller CJ, Sakhaee K, et al. Management of cystine nephrolithiasis with alpha-mercaptopropionylglycine. J Urol 1986;136:1003-8
36. Lerner SP, Gleeson MJ, Griffith DP. Infection stones. J Urol 1989;141:753-9
37. Curhan GC, Willett WC, Rimm EB, et al. Prospective study of beverage use and the risk of kidney stones. Am J Epidemiol 1996;143:240-7
38. Odvina CV. Comparative value of orange juice versus lemonade in reducing stone-forming risk. Clin J Am Soc Nephrol 2006;1:1269-74
39. Gettman MT, Ogan K, Brinkley LJ, et al. Effect of cranberry juice consumption on urinary stone risk factors. J Urol 2005;174:590-4
40. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 1993;328:833-8
41. Borghi L, Schianchi T, Meschi T, et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 2002;346:77-84
42. Pak CYC, Odvina CV, Pearle M, et al. Effect of dietary modification on stone risk factors. Kidney Int 2005;68:2264-73
43. Levy FL, Adams-Huet B, Pak CYC. Ambulatory evaluation of nephrolithiasis: an update of a 1980 protocol. Am J Med 1995;98:50-9
44. Pak CYC, Peterson R, Poindexter J. Prevention of spinal bone loss by potassium citrate in calcium urolithiasis. J Urol 2001;168:31-4
45. Peacock M, Bilezikian JP, Klassen PG, et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005;90:135-41
46. Pak CYC, Heller H, Pearle MS, et al. Prevention of stone formation and bone loss in absorptive hypercalciuria by combined dietary and pharmacological interventions. J Urol 2003;169:465-9
47. Dvorak MM, de Joussineau C, Carter DH, et al. Thiazide diuretic directly induce osteoblast differentiation and mineralized nodule formation by interacting with sodium chloride co-transporter in bone. J Am Soc Nephrol 2007;18:2509-16